Frontline Checkpoint Inhibitor Monotherapy in NSCLC

Program Overview

This learner-friendly 15-minute infographic activity is augmented by physician videos in an interactive approach to key safety and efficacy data for frontline pembrolizumab, atezolizumab, and cemiplimab monotherapies in advanced non-small cell lung cancer (NSCLC).

Credit Expired
0.25 CE Credit(s)
Expires: June 24, 2022

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Evaluate the survival advantage versus chemotherapy for current and emerging frontline checkpoint inhibitor monotherapies in advanced nondriver non-small cell lung cancer (NSCLC) with high PD-L1 expression

Activity Faculty


Ahmet Sezer, MD

Professor, Medical Oncology
Başkent University
Adana, Turkey

Head Shot YMS2312_0228_Goldberg (2)

Sarah B. Goldberg, MD, MPH

Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT

Brian Henick

Brian Henick, MD

Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

© Copyright 2023. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources